Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer, today announced that four abstracts with clinical
trial designs and clinical data of its innate cell engagers (ICE®)
have been accepted for presentation at the American Society of
Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7,
2022 in Chicago, IL.
The events include an oral presentation by Yago Nieto, M.D.,
Ph.D., professor of Stem Cell Transplantation and Cellular Therapy
at The University of Texas MD Anderson Cancer Center with an update
of the study that evaluates AFM13 pre-complexed with NK cells in
patients with relapsed/refractory CD30-positive lymphomas. In
addition, three “Trial in Progress” posters will be presented to
provide background information and introduce the study design of
the three ongoing AFM24 studies in which patients with
EGFR-positive solid tumors are treated with AFM24 monotherapy or
combinations with either Roche’s checkpoint inhibitor atezolizumab
or NKGen Biotech’s NK cell product SNK01.
Oral presentation details:
Title: Innate cell engager (ICE®) AFM13
combined with preactivated and expanded cord blood (CB)-derived NK
cells for patients with refractory/relapsed CD30+ lymphoma
Authors: Yago Nieto, Pinaki Banerjee,
Indreshpal Kaur, Roland Bassett, Lucila Kerbauy, Rafet Basar, Mecit
Kaplan, Lori Griffin, Daniel Esqueda, Christina Ganesh, Melissa
Barnett, Amin Alousi, Chitra Hosing, Jeremy Ramdial, Neeraj Saini,
Samer Srour, Sairah Ahmed, Swaminathan Iyer, Hun Lee, Ranjit Nair,
Raphael Steiner, Karenza Alexis, Andreas Harstrick, Elizabeth J
Shpall, Katayoun Rezvani
Oral session: Hematologic Malignancies –
Lymphoma and Chronic Lymphocytic Leukemia, Friday, June 3, 2022,
1:00 - 4.00 p.m. CDT
Poster details:
Title: A phase 1/2a open label,
multicenter study to assess the safety, tolerability,
pharmacokinetics, and efficacy of AFM24 in patients with advanced
solid cancers: Study design and rationale.
Authors: Omar Saavedra Santa Gadea, Elena
Garralda, Juanita Suzanne Lopez, Mark M. Awad, Jacob Stephen
Thomas, Crescens Diane Tiu, Daniela Morales-Espinosa, Christa Raab,
Bettina Rehbein, Gabriele Hintzen, Kerstin Pietzko, Paulien
Ravenstijn, Michael Emig, Anthony B. El-Khoueiry
Poster details:
Title: AFM24 in combination
with atezolizumab in patients with advanced EGFR-expressing solid
tumors: Phase 1/2a study design and rationale.
Authors: Omar Saavedra Santa Gadea, Eric
Christenson, Anthony B. El-Khoueiry, Andres Cervantes, Christa
Raab, Ulrike Gaertner, Kerstin Pietzko, Gabriele Hintzen, Paulien
Ravenstijn, Daniela Morales-Espinosa, Juanita Suzanne Lopez
Poster details:
Title: The combination of
CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous
natural killer cells in patients with advanced solid tumors.
Authors: Anthony B. El-Khoueiry, Paul Y. Song,
Jennifer Rubel, Dorna Y. Pourang, Christa Raab, Gabriele Hintzen,
Michael Emig, Pilar Nava-Parada
Poster session for all posters: Developmental
Therapeutics – Immunotherapy, Sunday, June 5, 2022, 8:00 – 11:00
a.m. CDT
Abstract release: The full abstracts will
become public at 5:00 p.m. EDT on Friday, May 26.
More details about the programs for the ASCO Annual Meetings are
available online at www.asco.org
About AFM13
AFM13 is a first-in-class innate cell engager (ICE®) that
uniquely activates the innate immune system to destroy
CD30-positive hematologic tumors. AFM13 induces specific and
selective killing of CD30-positive tumor cells, leveraging the
power of the innate immune system by engaging and activating
natural killer (NK) cells and macrophages. AFM13 is Affimed’s most
advanced ICE® clinical program and is currently being evaluated as
a monotherapy in a registration-directed trial in patients with
relapsed/refractory peripheral T-cell lymphoma (REDIRECT,
NCT04101331).
In addition, The University of Texas MD Anderson Cancer Center
is studying AFM13 in an investigator-sponsored phase 1/2 trial in
combination with cord blood-derived allogeneic NK cells in patients
with relapsed/refractory CD30-positive lymphomas (NCT04074746).
About AFM24
AFM24 is a tetravalent, bispecific innate cell engager (ICE®)
that activates the innate immune system by binding to CD16A on
innate immune cells and EGFR, a protein widely expressed on solid
tumors, to kill cancer cells. Generated by Affimed’s
fit-for-purpose ROCK® platform, AFM24 represents a distinctive
mechanism of action that uses EGFR as a docking site to engage
innate immune cells for tumor cell killing through
antibody-dependent cellular cytotoxicity and antibody-dependent
cellular phagocytosis.
Affimed is evaluating AFM24 in patients with advanced
EGFR-expressing solid malignancies whose disease has progressed
after treatment with previous anticancer therapies as monotherapy
and in combinations with other cancer treatments. AFM24-101, a
monotherapy, first-in-human phase 1/2a open-label, is a
non-randomized, multi-center, multiple ascending dose escalation
and expansion study. Additional details may be found at
www.clinicaltrials.gov using the identifier NCT04259450.
Furthermore, AFM24 is being evaluated in a phase 1/2a study in
combination with Roche’s anti-PD-L1 checkpoint inhibitor
atezolizumab (AFM24-102, NCT05109442). Affimed and NKGen Biotech
have initiated a phase 1/2a study (AFM24-103), investigating AFM24
in combination with SNK01, NKGen Biotech’s NK cell product
(NCT05099549).
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to give patients back their innate ability to
fight cancer by actualizing the untapped potential of the innate
immune system. The company’s proprietary ROCK® platform enables a
tumor-targeted approach to recognize and kill a range of
hematologic and solid tumors, enabling a broad pipeline of
wholly-owned and partnered single agent and combination therapy
programs. The ROCK® platform predictably generates customized
innate cell engager (ICE®) molecules, which use patients’ immune
cells to destroy tumor cells. This innovative approach enabled
Affimed to become the first company with a clinical-stage ICE®.
Headquartered in Heidelberg, Germany, with offices in New York, NY,
Affimed is led by an experienced team of biotechnology and
pharmaceutical leaders united by a bold vision to stop cancer from
ever derailing patients’ lives. For more about the company’s
people, pipeline and partners, please visit: www.affimed.com.
Investor Relations Contact
Alexander FudukidisDirector, Investor RelationsE-Mail:
a.fudukidis@affimed.comTel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin Vice President, Marketing and
CommunicationsE-Mail: m.sandin@affimed.com Tel.: +1 (484)
888-8195
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024